Form 4: NewAmsterdam Pharma CEO Michael Davidson Reports Share Transactions Following Milestone Achievement

CEO Michael Davidson reports acquisition and disposal of NewAmsterdam Pharma shares and restricted stock units (RSUs) related to a clinical development milestone achieved under the business combination agreement.

Summary

• Michael Davidson, CEO of NewAmsterdam Pharma Co N.V., reported transactions involving ordinary shares and restricted stock units (RSUs) on March 26, 2025.
• He acquired 30,992 ordinary shares as earnout shares related to a clinical development milestone achieved under the business combination agreement (BCA).
• Davidson also acquired 38,394 ordinary shares through the vesting of restricted stock units.
• He disposed of 12,258 ordinary shares to satisfy tax withholding obligations arising from the vesting of RSUs, with prices ranging from $22.88 to $23.22 per share.
• Following these transactions, Davidson beneficially owns 390,441 ordinary shares.
• He also acquired 38,394 restricted stock units (RSUs) as earnout RSUs pursuant to the BCA, which are fully vested and represent a contingent right to receive one ordinary share each.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the filing reflects the achievement of a clinical milestone, triggering the vesting of earnout shares and RSUs. However, the sale of shares to cover tax obligations tempers the overall positive sentiment.

Positives

• The achievement of a clinical development milestone triggered the issuance of earnout shares and RSUs to the CEO, indicating progress in the company's clinical programs.
• The vesting of RSUs suggests the CEO is incentivized and aligned with the company's long-term success.

Negatives

• The sale of 12,258 shares to cover tax obligations, while common, slightly reduces the CEO's direct shareholding.

Risks

• The document does not explicitly mention any risks.
• However, reliance on clinical milestones for earnout shares introduces a degree of uncertainty, as future milestones may not be achieved.

Future Outlook

The document does not contain explicit forward-looking statements, but the earnout shares and RSUs are tied to future clinical development milestones.

Industry Context

Form 4 filings are standard disclosures for company insiders and provide transparency into their transactions. The vesting of earnout shares and RSUs based on clinical milestones is a common practice in the biotech industry to align management incentives with company performance.

Comparison to Industry Standards

• Comparing NewAmsterdam Pharma to similar biotech companies like Madrigal Pharmaceuticals or Viking Therapeutics, which are also focused on cardiometabolic diseases, the use of milestone-based equity compensation is a standard practice.
• The specific terms of the BCA and the clinical milestones would need to be compared to industry benchmarks to assess their relative difficulty and potential value creation.

Stakeholder Impact

• Shareholders may view the achievement of the clinical milestone positively, as it indicates progress in the company's drug development pipeline.
• Employees may be motivated by the company's progress and the potential for future milestones.

Key Dates

Keywords

NewAmsterdam Pharma, Michael Davidson, Form 4, Beneficial Ownership, Ordinary Shares, Restricted Stock Units, RSU, Earnout Shares, Clinical Milestone, BCA